Therefore, the combination of low‐dose IL‐2 with conventional therapy significantly increases Treg cell numbers and maintains immune homeostasis, potentially alleviating symptoms in DM/PM patients while enhancing their anti‐infection capabilities. The gene discussed is IL2; the disease is polymyositis.